PharmaCyte Biotech
PMCB
24 hedge funds and large institutions have $710K invested in PharmaCyte Biotech in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 1 closing their positions.
467% more call options, than puts
Call options by funds: $17K | Put options by funds: $3K
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
14% more funds holding
Funds holding: 21 → 24 (+3)
0.34% less ownership
Funds ownership: 8.62% → 8.28% (-0.34%)
24% less capital invested
Capital invested by funds: $934K → $710K (-$224K)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$16.3K |
| 2 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$5.35K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.46K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.61K |
| 5 |
Renaissance Technologies
New York
|
+$325 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$41.9K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$26.1K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$10.6K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$855 |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$325 |
PMCB Hedge Fund Activity: Q1 2025 in Review
24 of the 7,463 institutional investors tracked by Wall St. Rank reported a position in PharmaCyte Biotech (PMCB) for Q1 2025, worth a combined $710K — down 24% from $934K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PMCB positions and 1 closed out — a net gain of 3 holders — while 4 added to existing stakes and 8 trimmed.
The largest buyer was UBS Group, adding an estimated $16.3K. The largest seller was Geode Capital Management, cutting an estimated $41.9K.
- 24 institutional investors held PharmaCyte Biotech (PMCB) as of Q1 2025, up from 21 in Q4 2024.
- Funds reported $710K of PharmaCyte Biotech stock for Q1 2025, down 24% quarter-over-quarter.
- 4 funds opened new PharmaCyte Biotech positions in Q1 2025 and 1 closed out, a net change of +3 holders.
- The largest PharmaCyte Biotech buyer in Q1 2025 was UBS Group, an estimated $16.3K added.
- The largest PharmaCyte Biotech seller in Q1 2025 was Geode Capital Management, an estimated $41.9K sold.
Based on aggregated 13F filings for Q1 2025.